Our recent studies have shown that the FoxM1B transcription factor is overexpressed in human glioma tissues and that the level of its expression correlates directly with glioma grade. However, whether FoxM1B plays a role in the early development of glioma (i.e., in transformation) is unknown. In this study, we found that the FoxM1B molecule causes cellular transformation and tumor formation in normal human astrocytes (NHA) immortalized by p53 and pRB inhibition. Moreover, brain tumors that arose from intracranial injection of FoxM1B-expressing immortalized NHAs displayed glioblastoma multiforme (GBM) phenotypes, suggesting that FoxM1B overexpression in immortalized NHAs not only transforms the cells but also leads to GBM formation. Mechanistically, our results showed that overexpression of FoxM1B upregulated NEDD4-1, an E3 ligase that mediates the degradation and downregulation of phosphatase and tensin homologue (PTEN) in multiple cell lines. Decreased PTEN in turn resulted in the hyperactivation of Akt, which led to phosphorylation and cytoplasmic retention of FoxO3a. Blocking Akt activation with phosphoinositide 3-kinase/Akt inhibitors inhibited the FoxM1B-induced transformation of immortalized NHAs. Furthermore, overexpression of FoxM1B in immortalized NHAs increased the expression of survivin, cyclin D1, and cyclin E, which are important molecules for tumor growth. Collectively, these results indicate that overexpression of FoxM1B, in cooperation with p53 and pRB inhibition in NHA cells, promotes astrocyte transformation and GBM formation through multiple mechanisms. Cancer Res; 70(7); 2951-61. ©2010 AACR.
Introduction
Malignant glioma, including the most common subtype, astrocytoma, is aggressive, highly invasive, and neurologically destructive. The prognosis for patients with malignant glioma is poor (1, 2) . Several pathways have been correlated with human gliomas, such as pRb, p53, epidermal growth factor receptor, platelet-derived growth factor (PDGF)/PDGF receptor, p16 INK4a , p19 ARF , telomerase, and Akt (3) (4) (5) (6) . Activation of the Akt pathway is strongly implicated in glioma development and progression. In human studies, Akt is activated in ∼80% of glioblastoma multiformes (GBM; ref. 3) . Activation of the Akt pathway in glioma is often achieved by the underexpression of its negative regulator phosphatase and tensin homologue (PTEN). Studies have shown that PTEN is underexpressed in almost all GBM tumors, compared with levels in normal brain tissue (7) . Several mechanisms may be associated with the underexpression of PTEN in gliomas, such as genetic alterations or promoter methylation (8) (9) (10) (11) . However, gene deletion, mutation, loss of heterozygosity, or promoter methylation in the PTEN gene is present in only about 50% of GBMs (7) (8) (9) (10) (11) . In addition, although PTEN genetic alterations are rare in low-grade gliomas, these tumors exhibit lower PTEN protein levels than does the normal brain tissue (7) . Furthermore, underexpression of PTEN in the absence of genetic alterations or promoter methylation is seen frequently in gliomas as well (8) . Thus, mechanisms for PTEN control at the transcriptional and posttranslational levels may be altered in glioma.
Ubiquitin-mediated degradation of PTEN has recently been reported, and neural precursor cell-expressed, developmentally downregulated 4-1 (NEDD4-1) has been identified as the E3 ligase for PTEN (12) . NEDD4-1 negatively regulates PTEN stability by catalyzing PTEN polyubiquitination. In fact, overexpression of NEDD4-1 has been shown to increase PTEN polyubiquitination in a dose-dependent manner (12) . Consistent with the tumor-suppressive role of PTEN, NEDD4-1 was reported to be an oncogenic protein that regulates tumorigenesis (12) . Overexpression of NEDD4-1 increased cellular transformation by K-Ras. Elimination of NEDD4-1 expression inhibited xenotransplanted tumor growth. Furthermore, NEDD4-1 regulates tumorigenesis by regulating Akt signaling through PTEN and the oncogenic activity of NEDD4-1 is PTEN dependent (12) . However, little is known about the regulation of NEDD4-1.
FoxM1 is a member of the Forkhead box (Fox) transcription factor family known for its function as a regulator of the cell cycle (13) (14) (15) (16) (17) . Results from recent studies have revealed that FoxM1 is substantially elevated in several aggressive human carcinomas and can contribute to oncogenesis in many tissue types (18) (19) (20) (21) (22) (23) (24) (25) . For example, using transgenic and knockout mouse models, studies have shown that FoxM1B plays essential roles in the development of hepatocellular carcinoma (20) , prostate carcinoma (21), lung cancer (22, 23) , and colorectal cancer in mice (24) . Moreover, FoxM1 is an essential molecule in the regulation of oxidative stress, which contributes to malignant transformation and tumor cell survival (16) .
Increasing evidence indicates that FoxM1 may also contribute to oncogenesis in glioma. For example, several studies found that aberrant expression of FoxM1 was a common molecular alteration in malignant glioma (25) (26) (27) . Another study that analyzed expression data from 201 GBM clinical specimens derived from TCGA showed the overexpression of FoxM1 in GBM specimens compared with nontumor controls (28) . In our own studies of the functional importance of this factor, we found that FoxM1B was the predominant FoxM1 isoform in human gliomas (25) . FoxM1 levels in human glioma tissue directly correlated with glioma grade and inversely correlated with the survival of GBM patients. In animal models, increased levels of FoxM1B expression in glioma cells enhanced the tumorigenicity, invasiveness, and angiogenesis of these cells (25, 29, 30) .
In this study, we sought to determine whether overexpression of FoxM1B induces the transformation of human astrocytes into glioma cells because FoxM1 expression is detected in low-grade glioma. We used immortalized NHA-E6/E7/ hTERT cells because human astrocytes seem to be more genetically stable than rodent cells (31) and individual events believed to be important in gliomagenesis might be more readily studied in the human cells (31) (32) (33) . Moreover, the fact that normal human astrocyte (NHA) cells were not transformed by E6/E7/hTERT suggests that inactivation of the p53 and pRb pathways was not sufficient to create malignant astrocytes and that additional molecular events are needed (31) . We found for the first time, to our knowledge, that FoxM1B expression in NHA-E6/E7/hTERT cells resulted in cellular transformation and GBM formation in nude mice due, at least in part, to its role in the regulation of NEDD4-1, the activation of Akt, and the induced expression of survivin, cyclin D1, and cyclin E.
Materials and Methods
Cell lines and culture conditions. The NHA-E6/E7/hTERT cell line and the Hs683 and HFU-251 glioma cell lines were previously described (25, 31, 33) . COS-1 cells were obtained from the American Type Culture Collection. All of the cell lines were cultured in DMEM supplemented with 10% fetal bovine serum (FBS).
Retrovirus production and transduction. Retrovirus was produced with pLXSN-FoxM1B or pLXSN plasmids using the Phoenix A retrovirus production system. NHA-E6/E7/hTERT cells were infected with the virus (10 multiplicity of infection) with 4 μg/mL polybrene for 24 h. To generate stable transduced cell lines, some infected cells were cultured with neomycin for 2 wk.
Northern blot analysis. Northern hybridization was done by using a [
32 P]dCTP-radiolabeled FoxM1 cDNA probe (25) . Equal mRNA loading was monitored by hybridizing the same membrane with a β-actin cDNA probe.
Western blot analysis. Standard Western blotting was done with antibody against FoxM1, cyclin E, cyclin D1, PTEN (Santa Cruz Biotechnology) or NEDD4-1, Akt, phospho-Akt, FoxO3a, phospho-FoxO3a (Cell Signaling Technology), and survivin (Novus Biologicals).
Animals. Female athymic BALB/c nude mice were purchased from the National Cancer Institute and were maintained in institutional facilities approved by the Association for Assessment and Accreditation of Laboratory Animal Care.
Colony formation in soft-agar assay. Cells (5 × 10 3 ) were mixed with 0.3% agar solution in DMEM containing 10% FBS and 200 μg/mL neomycin, and the solution was poured on top of a 0.60% agar layer in six-well tissue culture plates. Plates were incubated at 37°C in a humidified atmosphere containing 5% CO 2 for 21 d. Colonies were then stained with p-iodonitrotetrazolium violet (1 mg/mL) and examined microscopically.
Subcutaneous tumor growth. Cells (1 × 10 7 ) were injected s.c. into nude mice (25) . The length (L), width (W), and height (H) of the resulting tumors were measured once every 5 d. The volume of each tumor was calculated by using the formula 1/2 × L × W × H at every time point.
Intracranial human glioma xenograft model. Cells (1 × 10 6 ) were injected intracranially into nude mice as previously described (25) . Animals showing general or local symptoms were killed; the remaining animals were killed 90 d after glioma cell injection.
Histologic and immunohistochemical analysis of tumors. Tissue sections of brain tissue specimens were stained with H&E according to standard protocols. Tissue sections were also used for immunostaining with antibodies against CD31 (BD Biosciences), glial fibrillary acidic protein (GFAP, DAKO), phospho-Akt (Cell Signaling Technology), PTEN, cyclin E, cyclin D1 (Santa Cruz Biotechnology), and survivin (Novus Biologicals).
Cycloheximide chase experiments. Cells (5 × 10 5 ) were plated into six-well plates. Twenty-four hours later, 50 mg/ mL of cycloheximide were added to the cells and cycloheximide treatment was terminated at the indicated time points. Cell lysates were then prepared and the expression of PTEN was analyzed by Western blotting.
Chromatin immunoprecipitation assay. Cells (5 × 10 6 ) were prepared for the chromatin immunoprecipitation (ChIP) assay as according to the manufacturer's instructions with the ChIP assay kit (Cell signaling). Resulting DNA complexes were first immunoprecipitated using the indicated antibodies and then DNA was purified from the complexes. The DNA was then subjected to PCR to amplify the putative FoxM1 binding region 1 (−642 to −828 bp) or region 2 (−841 to −993 bp) of the NEDD4-1 promoter using the primers 5′-TCTTCGTCACTGCCTTCTG-3′ and 5′-TTGGACT-CGGGATCTGAAA-3′ or the primers 5′-TATG-GATGCCTTATTTGGTG-3′ and 5′-TGAACTAGGACCTCCTG-TAGAAT-3′, respectively.
Statistical analyses. The significance of the in vitro results was determined by using the Student t test (two tailed), whereas the significance of the in vivo data was determined by using the Mann-Whitney U test.
Results
FoxM1 induces malignant transformation of immortalized NHAs. We infected NHA-E6/E7/hTERT cells with pLXSNFoxM1B or control pLXSN retrovirus. The infected cells were plated for growth in soft agar. Both NHA-E6/E7/hTERT cells and NHA-E6/E7/hTERT cells infected with pLXSN were unable to grow in soft agar (Table 1 ; Fig. 1A ). However, colonies were obtained with NHA-E6/E7/hTERT cells infected with the virus containing FoxM1B (Table 1 ; Fig. 1A ). These results suggest that although inactivation of the p53 and pRb pathways is not sufficient to convert normal astrocytes into malignant glioma cells, such inactivation acts cooperatively with FoxM1B to achieve cellular transformation.
Immortalized NHAs that express FoxM1 are tumorigenic. Next, we created a series of cell lines immortalized by the expression of E6/E7/hTERT and expressing FoxM1B. To avoid clonal selection and variation, we carried out three independent infections of pLXSN-FoxM1B in NHA-E6/E7/ hTERT cells and pooled G418-resistant colonies to establish stable cell lines, designated as FoxM1B-transduced cell lines (NHA-E6/E7/hTERT/FoxM1B-1, NHA-E6/E7/hTERT/ FoxM1B-2, and NHA-E6/E7/hTERT/FoxM1B-3). FoxM1 protein expression was increased in FoxM1B-transduced NHA-E6/E7/hTERT cell lines (Fig. 1B) .
We then evaluated FoxM1-infected NHA-E6/E7/hTERT cells for their ability to form subcutaneous tumors in nude mice; tumors formed within 3 wk (Fig. 1C) . No tumors developed by 8 wk in mice injected with parental NHA-E6/E7/ hTERT or pLXSN-infected cells. Thus, the results show that NHA-E6/E7/hTERT/FoxM1 cells are tumorigenic.
FoxM1 induces GBM formation of immortalized NHAs. We used an orthotopic xenograft model of human glioma to study the growth of these cells in the brains of nude mice. Intracranially implanted NHA-E6/E7/hTERT or pLXSN-infected cells did not form tumors by 90 d after injection (Table 1 ). In contrast, intracranially injected FoxM1B-infected NHA-E6/E7/hTERT cells formed brain tumors in nude mice and significantly shortened their survival duration (Table 1) . We also examined the histologic features of brain tumors that arose from NHA-E6/E7/hTERT/ FoxM1 cells in the brains of nude mice. The lesions were characterized by high cellularity and invasiveness, were pleomorphic, and exhibited microvessel proliferation and necrosis (Fig. 1D) , all distinct histologic features of human GBM. In addition, the brain tumor cells were positive for GFAP, but the level of expression was less than that in astrocytes in the surrounding tissue, indicating a human astrocytic origin of the tumors (Fig. 1D ). These findings ) were implanted intracranially into nude mice. Mice were killed when they were moribund or on day 90. Brains were harvested and tumor formation was histologically analyzed. Results were shown for one representative experiment of two. ‡ P < 0.001. Increased FoxM1 expression leads to Akt activation. In animal studies, activation of Akt seems to be essential for the formation of GBMs from genetically modified neural progenitors and NHAs (33, 34) . Thus, we examined whether overexpression of FoxM1 affects the activation status of Akt in NHA-E6/E7/hTERT cells. We found that pLXSN-FoxM1B infection induced more phosphorylation and activation of Akt than did infection with retroviral pLXSN or Ras ( Fig. 2A) . In contrast, overexpression of FoxM1 did not affect extracellular signal-regulated kinase (ERK)-1/2 activation, a different pathway from Akt ( Fig. 2A) . NHA-E6/E7/hTERT/FoxM1B brain tumors also expressed phosphorylated Akt (p-Akt; Fig. 2B ). Furthermore, overexpression of FoxM1 in NHA-E6/E7/ hTERT by transient pLXSN-FoxM1B infection induced the nuclear translocation of Akt and the cytoplasmic retention of FoxO3a protein (Fig. 2C) , which have been reported as significant predictors of p-Akt status in gliomas (35) . These results indicate that increased FoxM1 expression leads to Akt activation and subsequently inhibits FoxO3a function.
Blocking Akt activation inhibits FoxM1-induced transformation of immortalized NHAs. To determine whether FoxM1 induces transformation of immortalized NHAs through the Akt pathway, we treated NHA-E6/E7/hTERT/ FoxM1 cells with phosphoinositide 3-kinase (PI3K) inhibitors LY294002 and wortmannin. Both treatments inhibited the expression of p-Akt in the cells (Fig. 2D, left) . Furthermore, blockade of Akt activation by LY294002 and wortmannin suppressed the transformation of immortalized NHAs, as determined by colony formation assay (Fig. 2D, right) . Therefore, these data suggest that Akt activation is an important step in the FoxM1-mediated transformation of immortalized NHAs into glioma cells.
Increased FoxM1 expression leads to PTEN reduction and Akt activation. It is known that PTEN is an important molecule that regulates Akt activity by inhibiting PI3K (36, 37) . To further define how FoxM1 activates the Akt pathway in NHA cells, we examined PTEN expression in these cells. Levels of PTEN expression were substantially lower in NHA-E6/E7/hTERT/FoxM1B cells than in NHA-E6/E7/ hTERT or NHA-E6/E7/hTERT/pLXSN control cells (Fig. 3A,   Figure 2 . Overexpression of FoxM1 increases p-Akt but not p-ERK-1/2. A, the expression of FoxM1, p-Akt, total Akt, FoxO3a, p-FoxO3a, ERK-1/2, and p-ERK-1/2 on NHA-E6/E7/hTERT/ FoxM1B cells or parental and NHA-E6/E7/hTERT/pLXSN cells was analyzed by Western blotting. B, paraffin sections from brain injected with pLXSN-and pLXSN-FoxM1B-transduced NHA-E6/E7/hTERT cells (tumors) were stained with antibody against p-Akt. C, immunofluorescent microscopic analyses of Akt activation and FoxO3a localization. NHA-E6/E7/hTERT cells were transiently infected with pLXSN-FoxM1B or pLXSN. Then, the cells were immunostained for Akt (green) and their nuclei were stained with 4′,6-diamidino-2-phenylindole (DAPI; blue). The cells were also immunostained for FoxO3a (green) and their nuclei were stained with DAPI (blue). Representative of three experiments. D, blocking Akt activation decreases the colony formation induced by FoxM1. NHA-E6/E7/hTERT cells were infected with retroviral-pLXSN or pLXSN-FoxM1B for 24 h and then treated with LY294002 (25 μmol/L) or wortmannin (0.1 μmol/L) for 2 h. Left, the expression of FoxM1, p-Akt, total Akt, FoxO3a, and p-FoxO3a was analyzed by Western blotting. Right, the colony-forming ability of the cells was determined by colony formation assay. Columns, mean colony numbers from a representative experiment done in triplicate; bars, SD. *, P < 0.01, compared with the no-treatment group. left). The observed decrease in PTEN expression in these cells was accompanied by enhanced Akt pathway signaling, as was evident by a concomitant increase in the level of p-Akt, but not in the level of total Akt (Fig. 3A, left) . NHA-E6/E7/ hTERT/FoxM1B brain tumors also had lower levels of PTEN expression than did brain tissues from the mice injected with NHA-E6/E7/hTERT/pLXSN cells (Fig. 3A, right) . Moreover, knockdown of FoxM1 in NHA-E6/E7/hTERT/FoxM1B cells restored PTEN expression and reversed the upregulation of p-Akt in the cells (Fig. 3B, left) . Furthermore, overexpression of FoxM1 in Hs683 glioma cells downregulated PTEN and upregulated p-Akt expression (Fig. 3B, right) .
FoxM1 regulates PTEN expression at the posttranscriptional level. To study the mechanism that may be responsible for the downregulation of PTEN by FoxM1, we first examined the RNA levels of PTEN and found that the transcriptional levels of PTEN were similar in both the NHA-E6/ E7/hTERT/FoxM1 and NHA-E6/E7/hTERT/pLXSN control cells (Fig. 3C) . Next, we inhibited protein translation in cells with the use of cycloheximide treatment and analyzed PTEN protein levels at the indicated times. As shown in Fig. 3D (left  and middle) , overexpression of FoxM1 in NHA-E6/E7/ hTERT/FoxM1 cells resulted in an increase in the endogenous PTEN degradation rate compared with NHA-E6/E7/ hTERT/pLXSN control cells. Overexpression of FoxM1 in COS-1 cells also resulted in a decreased level of exogenous PTEN protein (Fig. 3D, right) . Such a decrease in PTEN protein level can be blocked by the proteasomal inhibitor MG132 (Fig. 3D, right) . These results indicated that the decreased PTEN expression in FoxM1 overexpression cells was due, at least in part, to the increased stability of PTEN protein.
FoxM1 downregulates PTEN expression by regulating NEDD4-1. To study how FoxM1 regulates PTEN degradation, we first performed protein-protein binding experiments on FoxM1 and PTEN. We did not find direct binding of FoxM1 with PTEN (data not shown), indicating that the regulation of PTEN by FoxM1 is probably an indirect mechanism. On the other hand, NEDD4-1 has been identified as an E3 ligase that can promote PTEN ubiquitination and degradation. We determined that endogenous NEDD4-1 can indeed regulate PTEN in NHA-E6/E7/hTERT/FoxM1 by showing that the knockdown of NEDD4-1 by small interfering RNA (siRNA) in the cells caused an increase in endogenous PTEN (Fig. 4A) . Therefore, this result confirmed the role of NEDD4-1 as a PTEN E3 ligase in the cells.
We next examined the level of NEDD4-1 in NHA cells. As shown in Fig. 4B , the protein level of NEDD4-1 was upregulated in NHA-E6/E7/hTERT/FoxM1B cells compared with the levels in NHA-E6/E7/hTERT and NHA-E6/E7/hTERT/ pLXSN cells, whereas the protein level of PTEN was downregulated in NHA-E6/E7/hTERT/FoxM1B cells. Moreover, the mRNA level of NEDD4-1 was upregulated in NHA-E6/E7/ hTERT/FoxM1B cells (Fig. 4B, middle) . In contrast, knocking down FoxM1 in NHA-E6/E7/hTERT/FoxM1B cells inhibited the expression of NEDD4-1, restored PTEN expression, and inhibited p-Akt in the cells (Fig. 4B, right) .
To determine whether NEDD4-1 could be a direct transcriptional target of FoxM1, we scanned ∼2-kb promoter regions of the NEDD4-1 gene with the FoxM1 DNA binding consensus sequence (13) and two FoxM1 putative binding sites (−740 to −750 bp and −903 to −913 bp) were found in the promoter (Fig. 4C) . To determine whether FoxM1 binds directly to the human NEDD4-1 promoter, we performed ChIP assays using two pairs of PCR primers to DNA sequences (−642/−828 bp or −841/−993 bp) in the vicinity of these potential FoxM1 binding sites. Indeed, ChIP assays in NHA-E6/E7/hTERT/pLXSN or FoxM1B cells with antibodies specific to either FoxM1 or FoxO3a (control) showed that FoxM1 protein is directly bound to the endogenous NEDD4-1 promoter compared with the FoxO3a control (Fig. 4C) . Moreover, in the NHA-E6/E7/hTERT/FoxM1B cells that expressed high FoxM1 levels, there is an increased binding of FoxM1 protein to the promoter compared with that in NHA-E6/E7/hTERT/pLXSN (Fig. 4C) . These findings show that FoxM1 binds specifically to FoxM1 binding sites in the NEDD4-1 promoter in vivo, suggesting that NEDD4-1 could be a direct transcriptional target of FoxM1.
To examine whether FoxM1 regulates NEDD4-1 in other cells, Hs683 glioma cells were transfected with FoxM1. Overexpression of FoxM1 in Hs683 glioma cells upregulated NEDD-4, decreased PTEN, and increased p-Akt expressions (Fig. 4D, left) . Furthermore, COS-1 cells were cotransfected with PTEN in the presence or absence of FoxM1 overexpression. Overexpression of FoxM1 in COS-1 also caused an increase in NEDD4-1 and a decrease in exogenous PTEN protein (Fig. 4D, right) . Taken together, the above data indicate that FoxM1 regulates NEDD4-1 expression, and hence PTEN expression, in the cells.
FoxM1 induces multiple occurrences of cancer-related gene expression. To further explore the molecular mechanisms involved in FoxM1-mediated GBM formation, we measured the expression of cyclin D1, cyclin E, and survivin in FoxM1B-overexpressing cell lines and in the brain tumor tissues of mice. Some of these molecules have been previously reported to be downstream targets of Akt and/or FoxM1 and to be important factors for glioma proliferation (20, 24, 25, 38, 39) . Our results showed that cyclin D1, cyclin E, and survivin were also highly expressed in the FoxM1B-overexpressing cells and in the brain tumors that arose from injection of NHA-E6/E7/hTERT/FoxM1B cells ( Fig. 5A and B) . In addition, knockdown of FoxM1 expression downregulated these genes significantly in HFU-251 GBM cells (Fig. 5C ). These results indicate that overexpression of FoxM1 in NHA cells not only inhibits PTEN and activates the Akt pathway but also induces the expression of multiple cell cycle-related genes, which are important molecules for tumor growth.
Discussion
Although our previous studies had indicated that aberrant FoxM1B expression is critical to the regulation of tumorigenicity, invasion, and angiogenesis of human glioma cells, it was not known whether FoxM1B plays an important role in the transformation of human astrocytes into glioma cells. In this study, we found that overexpression of FoxM1 in immortalized human astrocytes not only transforms the cells but also causes them to progress into GBM cells in the brain. We also provided evidence that FoxM1 upregulated the expression of NEDD-4, which resulted in increased PTEN protein degradation. Furthermore, the increased PTEN protein degradation in turn led to the upregulation of activation of the Akt pathway, a potential mechanism for the development of GBM.
Glioma formation and progression are widely regarded as multistep processes resulting from a complex interplay between multiple genetic and epigenetic events (3-6, 31-33, 40, 41) . Studies have shown that the loss of p53 and pRb is not sufficient to induce glioma and that additional molecular events are needed such as Ras activation and PTEN loss (40, 41) . Our results support this finding; specifically, we found that a combination of FoxM1 overexpression, loss of p53 and pRb, and human telomerase reverse transcriptase overexpression is sufficient to induce NHA cells to transform into glioma.
Moreover, our results support the involvement of PTEN underexpression in transformation and in GBM formation. Brain-specific inactivation of PTEN in a mouse model caused increased astrocyte proliferation that may render these cells susceptible to neoplastic transformation (42, 43) . PTEN heterozygous knockout accelerated astrocytoma development in mice in which the Rb family proteins were inactivated (44) . Moreover, it has been shown that successive loss of each PTEN allele may contribute to de novo formation of highgrade astrocytoma and progression into glioblastoma (45) .
Numerous studies have suggested that PTEN can be inactivated not only by gene deletion and mutation but also by defects in posttranslational regulation during tumorigenesis (12, 46, 47) . Recent studies postulated that PTEN is subject to ubiquitination mediated by NEDD4-1, an E3 ligase, leading to PTEN degradation (12, 47) . Moreover, overexpression of NEDD4-1 was shown to induce PTEN degradation and promote K-Ras-mediated transformation (12) . In bladder cancers, the PTEN level was inversely correlated with the level of NEDD4-1 (12) . In breast cancer, NEDD4-1 was shown to be critical for targeting PTEN for degradation (47) . Therefore, these studies suggest that NEDD4-1 shows oncogenic activity that is PTEN dependent.
In the current study, we found that knockdown of NEDD4-1 in NHA-E6/E7/hTERT/FoxM1B cells caused an increase in endogenous PTEN, suggesting a role of NEDD4-1 in PTEN regulation in glioma cells. Furthermore, we showed that overexpression of FoxM1 downregulated PTEN expression in NHA-E6/E7/hTERT, Hs683, and COS-1 cells (all with wild-type PTEN). The mechanism for the overexpression of FoxM1 that accelerates PTEN degradation is as follows: FoxM1 regulates the expression of NEDD4-1, which promotes PTEN ubiquitination and degradation in these cells.
PTEN inactivation could result in uncontrolled PI3K/Akt signaling activation, a mechanism of tumor formation. We have observed that increased expression of FoxM1 in NHA-E6/E7/hTERT caused a significant increase in the level of pAkt and induced tumor colony formation in a soft-agar assay and tumor formation in a mouse brain tumor model. Moreover, the PI3K-specific inhibitors LY294002 and wortmannin can inhibit FoxM1-induced colony formation in vitro. Therefore, the results indicate that PI3K/Akt activation plays an important role in glioma formation.
Several studies have reported that cyclin D1 and cyclin E expressions correlate significantly with the degree of malignancy in astrocytomas (48) . Survivin expression is also increased in GBMs and correlates with patient survival (49) . In this study, we found that FoxM1B overexpression in glioma cells significantly increased survivin, cyclin D1, and cyclin E expression, consistent with findings in other types of cells (5, 11) . Thus, the molecular mechanisms by which FoxM1 regulates the growth of glioma cells are associated with increased expression of these molecules that function as cell cycle regulators and/or inhibitors of tumor cell apoptosis and are critical for tumor cell proliferation.
In summary, our findings show that FoxM1 plays an important role in promoting astrocyte transformation and GBM formation through regulation of multiple factors. Of more importance, we have provided a new mechanism of FoxM1-induced transformation and GBM formation involving the overexpression of FoxM1, which upregulates the expression of NEDD4-1 and hence destabilizes PTEN and activates the Akt pathway. Our findings strongly suggest that FoxM1 plays an important role in glioma transformation and may be a therapeutic target for glioma.
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